Company profile: U.S. Stem Cell
1.1 - Company Overview
Company description
- Provider of regenerative medicine and autologous cellular therapies for degenerative conditions, offering in-clinic solutions and training for physicians, regenerative medicine solutions for veterinary patients, and collaboration with industry innovators on R&D of cell-based therapeutics aimed at repairing damaged tissue.
Products and services
- Full Service: Delivers in-clinic regenerative medicine systems for physicians, supplying a range of treatments for degenerative conditions within clinical settings
- Training for Physicians: Offers autologous cellular therapy training programs that teach physicians to apply regenerative medicine for treating degenerative conditions
- Developing the future of medicine: Focuses on cell-based therapeutics that repair damaged tissue to treat disease, driving advancement in regenerative medicine
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to U.S. Stem Cell
Artegraft
HQ: United States
Website
- Description: Provider of biologic vascular grafts derived from bovine carotid arteries, processed and sold for implantation primarily in hemodialysis patients, offering surgeons a biological alternative to synthetic grafts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artegraft company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
TandemLife
HQ: United States
Website
- Description: Provider of innovative medical device products for cardiologists and cardiac surgeons worldwide, delivering unique solutions for patients requiring circulatory support, including the FDA-cleared TandemHeart System that provides extracorporeal circulatory support in minutes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TandemLife company profile →
Veryan Medical
HQ: United Kingdom
Website
- Description: Provider of three-dimensional Nitinol vascular stents for peripheral arterial disease, including the BioMimics 3D Vascular Stent System, a self-expanding stent with 3D helical geometry designed to impart a gentle helical shape to the stented artery to provoke swirling flow, increase wall shear stress, reduce intimal hyperplasia, improve biomechanical compatibility, and reduce stent fracture risk, and the MIMICS clinical program (MIMICS-RCT, MIMICS-2, MIMICS-3D) evaluating safety, effectiveness, and performance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veryan Medical company profile →
Shockwave Medical
HQ: United States
Website
- Description: Provider of intravascular lithotripsy (IVL) solutions for treating calcified coronary and peripheral arteries, including balloon dilatation catheters with lithotripsy electrodes that increase lesion compliance prior to low‑pressure dilation to limit injury to healthy tissue. Offerings include Shockwave C2+, L6, M5+, S4 IVL catheters, the IVL Generator, and the Shockwave Reducer System for refractory angina pectoris.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shockwave Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for U.S. Stem Cell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to U.S. Stem Cell
2.2 - Growth funds investing in similar companies to U.S. Stem Cell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for U.S. Stem Cell
4.2 - Public trading comparable groups for U.S. Stem Cell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →